Free Trial

Aditxt Q2 2023 Earnings Report

Aditxt logo
$0.24 -0.02 (-9.37%)
(As of 12/18/2024 05:45 PM ET)

Aditxt EPS Results

Actual EPS
-$1,472.00
Consensus EPS
-$4,624.00
Beat/Miss
Beat by +$3,152.00
One Year Ago EPS
N/A

Aditxt Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
$0.36 million
Beat/Miss
Missed by -$140.00 thousand
YoY Revenue Growth
N/A

Aditxt Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Missed Nvidia? Buy Elon Musk’s “Silent Partner” (Ad)

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Aditxt Earnings Headlines

Aditxt Advances ADI-100 Therapy to Human Trials
Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Drop in Short Interest
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Appili Therapeutics shareholders vote in favor of Aditxt transaction
See More Aditxt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aditxt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aditxt and other key companies, straight to your email.

About Aditxt

Aditxt (NASDAQ:ADTX), a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

View Aditxt Profile

More Earnings Resources from MarketBeat

Upcoming Earnings